Background & Aims: Chronic hepatitis c (CHC) and liver fibrosis progress more rapidly in men and menopausal women than in women of reproductive age. We investigated the associations among menopause, sustained virological response (SVR), and liver damage in patients with CHC.
Introduction
Appraisal of the clinical course of chronic hepatitis C (CHC) has revealed several striking differences between men and women. The progression of fibrosis is more than twice as fast in men, 1, 2 even when potential confounding factors like age, duration of infection, or metabolic features are accounted for by multivariate analysis. 1, 3 There are conflicting data about SVR rates in women; some studies report that response rates are not significantly different from those of men, 4 whereas others have identified female sex as an independent factor associated with SVR. 5 This inconsistency might arise from the fact that the female cohorts have always been evaluated as whole, without taking into account differences in responses due to hormonal state.
The reduced rate of fibrosis among women disappears after menopause; in fact, postmenopausal women have accelerated progression of fibrosis, 6 ,7 compared with men, which is slowed by long-term estrogen exposure with hormone replacement therapy (HRT). 7 Postmenopausal women are also at higher risk of developing hepatocellular carcinoma (HCC); there is a more balanced ratio of men:women in later life that results from the higher incidence of HCC in older women. 8, 9 Antiviral therapy greatly improves the natural course of CHC when it results in a sustained virological response (SVR), 10 even in patients with established cirrhosis. 11 Negative predictive factors for SVR include older age, [12] [13] [14] which might coincide with menopause. However, no studies have evaluated the impact of menopause itself on response to antiviral therapy.
We therefore evaluated the impact of menopause on SVR and on histological features in a prospective study. We collected data on the type and timing of menopause, parity, and the use and duration of hormone replacement therapy (HRT) in a cohort of 1000 patients with CHC undergoing standard antiviral therapy with pegylated interferon (PEG-IFN) and ribavirin (RBV).
Methods

Patients
From January 2002 to December 2008, 1000 consecutive patients with CHC were recruited to receive standard antiviral treatment at the Gastrointestinal and Liver Units of the University Hospitals of Modena and Bari. Eligible patients were 18 years of age or older, with compensated liver disease due to chronic HCV infection (any fibrosis stage, including compensated cirrhosis), a detectable plasma HCV RNA level and had not been previously treated for hepatitis C. All patients had undergone liver biopsy within 1 year prior to enrollment. All biopsies were reviewed and scored according to Ishak et al. 15 by a single pathologist (L.L.) unaware of patient identity or history. The percentage of hepatocytes containing macrovesicular fat was determined for each 10x
field and steatosis was classified as: absent-mild (< 5%); moderate: (≥5 to <20%); or severe (≥20%).
Patients were excluded if they were coinfected with human immunodeficiency virus or hepatitis B, any other cause of liver disease, severe depression or psychiatric disorder, or active substance or alcohol consumption of <20g/day in the last year or more, evaluated by a specific questionnaire.
The study was approved by the institutional review boards at the two centers and was conducted in accordance with provisions of the Declaration of Helsinki and Good Clinical Practice guidelines.
Clinical and laboratory assessment
The following data were collected at the time of liver biopsy: age, sex, weight, height, body mass index (BMI), and in women only: occurrence, type (spontaneous, surgical) and age at menopause, length of estrogen deprivation, use and duration of HRT, number of full term pregnancies and of abortions. Menopause was defined as no menstrual periods for 12 consecutive months and was defined as "early" when present for less than 5 years.
At the time of biopsy, serum levels of ALT, γ-glutamyl transpeptidase (GGT), alkaline phosphatase, platelet count, ferritin, glucose, and insulin were obtained. Insulin resistance (IR) was determined with the homeostasis model assessment (HOMA) method. 16 HCV-RNA was quantified by Abbott RealTime HCV assay (Abbott Molecular Inc., Des Plaines, IL) and genotyped by Innolipa (Innogenetics, Gent, Belgium).
Antiviral Treatment Schedule and Outcomes
Standard antiviral treatment consisted of either (1) 
Statistics
Continuous variables were summarized as mean ± standard error and categorical variables as frequency and percentage. The Student t-test and analysis of variance were used when appropriate.
Multiple logistic regression models were used to assess the relationship between 1) SVR, 2) severe fibrosis (Ishak staging ≥3), 3) severe necroinflammation (Ishak grading ≥8), 4) presence of steatosis and presence and the demographic, metabolic, and histological characteristics of patients.
In the statistical models, the dependent variables were coded as 1=present versus 0=absent. We included all patients who received at least one dose of pegylated interferon (intention-to-treat analysis).
In the female group, we also considered age at menopause, type of menopause (spontaneous, surgical), length of estrogen deprivation (3 different periods were evaluated: less than 5 years, 5 to 10 years and more than 10 years), use and duration of hormone replacement therapy (HRT), number of full term pregnancies and abortions. Variables associated with the dependent variable in univariate analyses (probability threshold, P < .10) were included in the multivariate regression models.
To avoid colinearity effects, menopause and length of estrogen deprivation were not included in the same multivariate model.
Regression analyses were performed using PROC LOGISTIC, PROC REG, and subroutines in SAS (SAS Institute, Inc., Cary, NC).
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Results
Baseline features of all 1.000 patients according to sex are shown in supplementary table 1. Ninetynine patients (9.9%) had a diagnosis of cirrhosis: cirrhosis was more frequent in men (12.3%) than women (6.7%) (P = .003), despite the latter being significantly older (52 vs. 48 years, P <.001).
Characteristics of Female Patients
At enrollment, 274 out of 442 women (62.0%) were menopausal. Significant independent predictors of SVR failure by multivariate analysis were genotype 1/4, necroinflammatory activity and GGT levels (Supplementary Table 2 ). 
Influence of menopause on response to antiviral therapy
Cytokines levels
Regardless of reproductive status, HCV-positive women had significantly higher serum levels of both TNF-α and IL-6 compared to controls (P < .0001 for all combinations) ( Figure 1A ). IL-6 levels in women of reproductive age were significantly lower than those in early post-menopausal women [2.6±1.5 vs 8.9±10.3 pg/ml; P = .007] and were lower, although to a lesser degree, than those in late post-menopausal women [2.6±1.5 vs 4.8±8,2 pg/ml; P = .017]. When only nulliparous women were considered, the difference in IL-6 levels between women of reproductive age and post-menopausal women was greater [3.2±2.2 vs. 42.3±18.2 pg/ml; P < .0001] and a small but significant difference was found also in TNF-α levels (27.0±3.1 vs. 29.2±2.5; P = .001)( Figure   1A 
Discussion
In this prospective study of 1000 consecutive patients with CHC, we found that menopause is independently associated with the severity of liver damage and with a remarkably lower likelihood of achieving SVR.
Various lines of evidence support a link between menopause and the severity of fibrosis in CHC patients. Recent studies suggest that post-menopausal women have accelerated progression of fibrosis, 6, 7 which is prevented by long-term estrogen exposure from HRT. 7 In this large cohort of female HCV patients, we confirmed that liver inflammation and higher levels of GGT (a known surrogate marker of metabolic alterations and of TNF-α up-regulation) 21 , are independently associated with severe fibrosis. We also identified the length of estrogen deprivation as a strong independent risk factor for fibrosis: the longer the menopausal period, the higher the risk of severe fibrosis. It was 5-fold higher in women who had been menopausal for more than 10 years in comparison with early menopausal women.
We found menopause to be significantly correlated with necro-inflammation, steatosis and metabolic alterations (high cholesterol and glucose). Accordingly, a recent clinical study showed a higher prevalence of steatosis in post-menopausal CHC patients who were more than 55 years old. 13 Experimental studies are in line with our clinical data on the association between menopause and liver damage, showing that menopause is associated with a pro-inflammatory state that can drive fibrosis progression and lead to HCC. 8 In addition, some experimental data also indicate a potential role of estrogen insufficiency in steatogenesis. 22, 23 Menopause coincides with older age, which has been identified as a negative predictive factor for a SVR. 13, 14 However, the influence of menopause itself on response to antiviral therapy has not been investigated. We examined age and menopause in multivariate analysis and found that age was not independently correlated with SVR, whereas menopause was. Our findings indicate that menopause is associated with a remarkable and unrecognized resistance to antiviral therapy, especially in carriers of genotype 1 HCV. Moreover, our data indicate that early stages of menopause (estrogen deprivation for less than 5 years) correlate with failure of antiviral therapy. This is particularly evident in women with genotype 1 HCV, who have less resistance to antiviral therapy with the passage of years after the onset of menopause. A possible explanation for this finding is that hepatic levels of TNF-α and circulating IL-6 are upregulated at the time of menopause. Another, unlikely, explanation is that occasional consumption of NSAIDs or unreported use of alcohol, causes levels of both cytokines to decrease after menopause, and hepatic expression of TNF-α levels become non-significantly different from those of women of reproductive age. ( Figure 1C, panel a) . A similar phenomenon has been described regarding bone loss and levels of IL-6, which affect bone loss less with time after menopause, becoming insignificant after 10 years. 24 It is interesting that in men, who had levels of cytokines that were constant yet greater than those of women at all age groups tested, the OR of not achieving an SVR was not significantly different among those younger than 45 years or older than 55 (i.e. in 2 age groups similar to those of women of reproductive age or menopausal females).
Although our study was not designed to clarify the pathogenesis of this association, the results do suggest several hypotheses. We focused our attention on levels of TNF-α and IL-6; these cytokines undergo large changes during in menopause 25 and in HCV infection, during which their levels are greatly up-regulated, [26] [27] [28] [29] and they are able to interfere with antiviral response. Our data show that the occurrence of menopause is associated with a large additional increase in circulating IL-6, a striking increase in hepatic TNF-α, and an increase in the expression of SOCS3 in the liver.
While there are no reports linking serum IL-6 levels with resistance to IFN, TNF-α has been implicated as an independent factor associated with response to IFN, 21, [29] [30] and hepatic SOCS3 is reportedly the strongest factor influencing the outcome of interferon-based antiviral therapy, [31] [32] [33] [34] especially in patients with genotype 1. 33 SOCS3 is induced by HCV core protein, 35 and also by IL-6 and TNF-α. 31, 32 These data support the hypothesis that menopause determines a switch to a systemic and hepatic pro-inflammatory state 25 in which increased IL-6 and TNF-α production contribute to the observed resistance to IFN-based therapies. Women entering menopause would rapidly go from an estrogen-protected environment, where HCV-mediated inflammation is limited, to an estrogen-deprived one in which inflammation becomes less controlled and resistance to antiviral therapy increases remarkably, thus increasing the risk of developing severe fibrosis.
We have also confirmed that genotype 1 and higher GGT levels are independent negative predictors of SVR, both for the entire cohort and when women are considered as a group. Although hidden alcohol or drug abuse cannot be excluded in principle to explain GGT alteration, the bias, if present, was equally shared by all groups, the methodology of ascertainment being the same for all.
More relevant, in this context, is the demonstrated relationship between GGTs levels and hepatic TNF-α mRNA, which in turn strongly related with non response in HCV patients 21 .
The study has some limitations. In particular we cannot rule-out that lack of data on vitamin D serum levels, a recently recognized factor influencing SVR achievement 36 , could affect the interpretation of our results, as well as the absence of data about other adipokines/cytokines.
In conclusion, our data from a large cohort of European women with CHC show that menopause is associated with profound changes in TNF-α and IL-6 levels. These changes are greater than those resulting from HCV infection in women of reproductive age and result in a more pronounced inflammatory state, more rapid progression to fibrosis and a hitherto unrecognized resistance to antiviral therapy. This suggests that CHC in women should be treated early, disregarding the fact that liver disease is milder in women of reproductive age, as this condition will last only as long as the estrogen-exposed period. Alternative strategies should be tested for HCV-positive women presenting in early post-menopause. We are currently examining the combination of HRT with PEG IFN/Ribavirin therapy in a controlled randomized trial (EudraCT 2008-001260-36). For levels of TNF-α, there were no significant differences between women of reproductive ages and post-menopausal women; the difference was significant when only nulliparous women were considered (P = .001). In men, levels of TNF-α were similar in all 3 age groups (difference non significant between all 3 combinations).
Legends to Figures
For IL-6, there was a significant difference between women of reproductive age and women at early post-menopause (P = .007), those at early and late post-menopause (P = .004), and women of reproductive age and women at late post-menopause (P = .017). Levels of IL-6 levels were also significantly higher among post-menopausal women, with and without history of pregnancies in comparison with women of reproductive age (P < .0001). In men, IL-6 levels were high in all 3 age groups considered without significant differences between each group. They were also significantly higher than in each female group evaluated (p<.0001 for all combinations) but nulliparous postmenopausal women (p=.025, p=.098, p=.393 for <45 years, 50-55 and > 60 years-old men respectively). Data are given as mean ± standard deviation or as number of case (%).
* P < .0001 .020
.003
Abbreviation: y, years; IU, international units; GGT, γ-glutamyltranspeptidase; HOMA, homeostasis model assessment; HCV-RNA, hepatitis C virus ribonucleic acid. Data are given as mean ± standard deviation or as number of cases (%). 
Supplementary
